Our healthcare equity research is broad in scope and in-depth in content and analysis. In addition to company-specific research, our team publishes sector overviews that seek to identify emerging trends and ways investors can benefit from these changes as well as inherent risks. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals, and specialty pharmaceuticals.
Matt Biegler is a Senior Analyst covering Emerging Biotechnology. Prior to joining Oppenheimer, Matt worked with Mark Breidenbach covering Biotechnology. Prior to his Wall Street career, Matt spent over five years in the healthcare industry, most recently as a Consultant at Parexel International, a Contract Research Organization. His areas of expertise include clinical trial design and strategy. Matt holds a Bachelor’s degree in Biochemistry and Molecular Biology from Boston University, and a Master’s in Biotechnology from the Columbia University Graduate School of Arts and Sciences.
Mark Breidenbach is an Executive Director and Senior Analyst covering Emerging Biotechnology. Mark was most recently at Roth Capital Partners as a lead Analyst covering Biotechnology and prior to that was a Managing Director and Senior Biotechnology Analyst at H.C. Wainwright & Co.. Prior to his Wall Street career, Mark was a Locum Scientist at Nature Publishing Group, and an Associate Specialist in Glycoproteomics and Metabolic Engineering at the Department of Chemistry, University of California Berkeley. Mark holds a PhD in Molecular and Cellular Physiology from Stanford University, a M. Phil. from the Department of Molecular Biophysics and Biochemistry at Yale University, and a dual BA in Biology and Chemistry from Cornell University.
Biotechnology and Diagnostics
Kevin DeGeeter is Managing Director and Senior Analyst covering Biotechnology and Diagnostics. Prior to re-joining Oppenheimer, Kevin was Senior Analyst covering Biotechnology at Ladenburg Thalmann, and focused on oncology, infectious diseases, cell therapy and molecular diagnostics. He has 20 years of buy-side and sell-side research experience including senior analyst positions with J.P Morgan, Paine Webber, Natexis Bleichroeder and Manning & Napier Advisors. He was previously at Oppenheimer & Co. from 2007-2009, also as a Senior Analyst covering Biotechnology. He received a BA. from Colgate University.
Leland Gershell is a Managing Director and Senior Analyst covering BioPharmaceuticals. Prior to joining Oppenheimer, Leland was Chief Financial Officer of Capricor Therapeutics and Tonix Pharmaceuticals. Leland also has both sell-side and buy-side experience and began his career on Cowen's biotechnology research team, where he provided sole coverage focused in the small and mid-cap segment. Leland has also authored numerous editorial and review articles and is an inventor on patents for Merck's Zolinza®. He earned his MD and Ph.D. in Organic Chemistry from Columbia University and his BA magna cum laude in Chemistry and Asian Studies from Dartmouth College.
Justin Kim is a Senior Analyst covering Biotechnology. Before joining Oppenheimer, Justin worked on the Biotechnology Equity Research teams at Cantor Fitzgerald and FBR & Company. Justin started his equity research career at Wedbush Securities covering Healthcare Managed Care before focusing on Biotechnology. Justin holds a B.S. in Mechanical Engineering from Columbia University and an M.B.A. from Washington University in St. Louis.
Steven M. LichtmanTitle:
Steven Lichtman is Managing Director and Senior Analyst for Medical Devices. Steve brings extensive experience in the Medical Devices sector, having previously held that role at JMP Securities and also Banc of America Securities where he focused on several medical device sectors, most notably orthopedics/spine. In 2007, he ranked in the top five for his orthopedics coverage in the Greenwich analyst survey. Prior to Banc of America, Steve was the Senior Associate on leading Medical Devices teams at Credit Suisse First Boston and Schroder & Company, Inc. Steve received a BA from Duke University in Economics & Public Policy Studies and an MBA from New York University's Stern School of Business.
Healthcare Information Technology
Mohan Naidu is a Managing Director and Senior Analyst covering the Healthcare Information Technology (HCIT) sector. Mohan joined us from Stephens, Inc. where he had been a Senior Analyst covering HCIT since 2013. Prior to Stephens, Mohan spent five years as a member of the highly ranked HCIT equity research team at Piper Jaffray & Co. Before his career as a research analyst, Mohan worked at GE Healthcare IT for seven years, first as a Senior Lead System Designer and later as a Product Development Manager. Mohan holds a Bachelor of Technology in Chemical Engineering from the University of Madras in India; a Master of Science in Computer Engineering from Syracuse University; and a MBA from the Kellogg School of Management. He also holds the CFA designation.
Jay Olson, CFATitle:
Jay Olson is Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jay covered SMID-cap names and worked on the Large Cap Pharmaceuticals team at Goldman Sachs for 4 years after 4 years on the #1 II-ranked Large Cap Pharmaceuticals team at Sanford Bernstein. Prior to Wall Street, Jay spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development. Jay received an MBA in Finance and an MS in Chemical Engineering both from MIT, and a BS in Chemical Engineering from Tufts University. He also holds the CFA designation.
Bio & Specialty Pharmaceuticals
Esther Rajavelu is an Executive Director and Senior Analyst covering Biotech & Specialty Pharmaceuticals. Prior to joining Oppenheimer, she was part of the Major and Specialty Pharmaceuticals equities research team at Deutsche Bank, where she launched as lead analyst on small and mid-cap companies. Esther has over 10 years of advisory experience in the life sciences sector including her time as an investment banker focused on Biotechnology transactions, and as a business strategy consultant to Major Pharmaceutical companies. She received a BA from Wesleyan University and an MBA from The Wharton School at the University of Pennsylvania.
Hartaj Singh is Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Hartaj was Managing Director and Senior Biotechnology Analyst at BTIG Securities. Hartaj began his sell-side career at Lehman Brothers and subsequently moved to the buyside covering Biotechnology at Visium Asset Management and Tecumseh Partners. He began his career as a Clinical Trial Project Manager for ClinTrials Research and also worked as a Strategic Analysis Manager for Johnson & Johnson, both of which give him critical experience in clinical trial design. Hartaj has a BA in Biology from Case Western Reserve University and also did extensive graduate work in Computational Neurobiology. He also holds an MBA from Duke University’s Fuqua School of Business.
Silvan Tuerkcan, Ph.DTitle:
Silvan Tuerkcan Ph.D is a Senior Analyst covering Biotechnology. Before joining Oppenheimer, Silvan worked at Goldman Sachs as a Global Investment Research Ph.D. fellow. In addition to his sell-side experience Silvan was a consultant at Oxbridge Biosciences Roundtable and was a Founder of Phaeton Biotechnology, which was done in conjunction with Stanford School of Medicine and the Office of Technology Transfer. Silvan holds a BS in Physics from McGill University, a MS in Engineering Physics from TU Munich, and a Ph.D in Biophysics from Ecole Polytechnique (France). He also holds a Certificate in Entrepreneurship & Innovation from Stanford Graduate School of Business.
Michael Wiederhorn is Managing Director and Senior Analyst covering Healthcare Providers and Services. His coverage focuses on managed care, hospitals, nursing homes, home health, hospice, emergency services, and related healthcare services. He has over fifteen years of experience in healthcare consulting and research and in 2013, he was honored as a top ranked Earnings Estimator in Health Care Providers & Services 2013 by Financial Times/Starmine. In addition, in 2009 and 2010, Michael was ranked the #1 brokerage analyst for Medical Care by Forbes Magazine. Prior to entering equity research, Michael was a management consultant at Ernst and Young, serving the healthcare industry. He has a Masters in Health Policy and Management from Harvard University and BA in American History from the University of Pennsylvania.